BridgeMD
Exploratory study of the expression of the serotonergic 5-HT4 receptor in Parkinson's disease
EU CTIS ID: 2022-503089-57-00
What this study is testing
The main objective is to compare the expression of the 5-HT4 receptor in patients with mild to moderate Parkinson's disease compared to age-matched healthy controls (controls)
- Phase II and Phase III (Integrated)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Clinically established or probable diagnosis of Parkinson's disease according to the criteria defined by the Movement Disorder Society at a Hoehn and Yahr stage ≤ 3 (for patient only)
- Duration of disease progression between 2 and 8 years (for patient only)
- MoCA ≥ 20/30 (for patient only)
- Age between ≥ 50 and ≤ 85 years old
- if woman , postmenopausal woman
- Affiliated to a social security scheme or similar
You likely can't join if
- Diagnosis other than Parkinson's disease ( for patient only)
- Deprivation of liberty by judicial or administrative decision, person subject to a legal protection measure
- BMI ≥ 35kg/m2
- Presence of depression (BDI-2 score ≥21), anxiety (Parkinson Anxiety Scale, PAS score ≥14) or apathy (STARKSTEIN score ≥14) - for healthy volunteers only
- Cognitive impairment (MOCA score ≤26) (for healthy volunteers only)
- Current or past neurological or psychiatric pathology (for healthy volunteers only)
See the full eligibility criteria
- Clinically established or probable diagnosis of Parkinson's disease according to the criteria defined by the Movement Disorder Society at a Hoehn and Yahr stage ≤ 3 (for patient only)
- Duration of disease progression between 2 and 8 years (for patient only)
- MoCA ≥ 20/30 (for patient only)
- Age between ≥ 50 and ≤ 85 years old
- if woman , postmenopausal woman
- Affiliated to a social security scheme or similar
- Having given their written consent to participate
- Level of study: ≥ 6 years of schooling
- No history of neurological or psychiatric disease (healthy volunteers only)
- Diagnosis other than Parkinson's disease ( for patient only)
- Deprivation of liberty by judicial or administrative decision, person subject to a legal protection measure
- BMI ≥ 35kg/m2
- Presence of depression (BDI-2 score ≥21), anxiety (Parkinson Anxiety Scale, PAS score ≥14) or apathy (STARKSTEIN score ≥14) - for healthy volunteers only
- Cognitive impairment (MOCA score ≤26) (for healthy volunteers only)
- Current or past neurological or psychiatric pathology (for healthy volunteers only)
- Serious and progressive medical pathology
- Treated with specific serotonin inhibitors (SSRIs), specific noradrenaline inhibitors (SNRIs), tricyclic antidepressants, monoamine oxidase inhibitors (MAOIs) and neuroleptics in the last 3 months
- Use of recreational drugs interfering with the serotonergic system (ecstasy, MDMA) or opioids (cannabis, opiates) in the last 3 months or chronic use
- Contraindication to magnetic resonance imaging (MRI) or positron emission tomography (PET)
- Participation in the last year to a study using ionizing radiation or concomitant participation in another research project involving the human being that may interfere with the results or the conclusions of this study
- Exceeding the annual amount of compensation authorized for participation in research protocols
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.